Why Invest?

NanoRepro AG wants to be a leading international provider of rapid diagnostics (self-tests) for domestic and clinical use and to expand its market potential steadily. NanoRepro will continue to pursue this long-term strategy consistently and exploit its opportunities. The following factors should contribute to an increase in value of the shares:

Extensive portfolio of own market-ready products

Today NanoRepro AG has launched 24 rapid tests for family planning line, health care line, allergy / food intolerance, as well as self tests for professional use (B2B) and six alphabiol food supplements. Even though the market is generally competitive in terms of pregnancy tests and ovulation tests, some of the tests have a few or no competing products (e.g. VagiQUICK, MilchCHECK)

Expansion of the product range offers growth opportunities

In addition to the existing products, further promising tests are under development. For the coming years product approvals and market launches are planned, in the areas of sexually transmitted diseases and infectious diseases. In addition, the Company plans to provide the portfolio with complementary products such as food supplements in addition to the existing tests in order to create an increased benefit for the consumer and to bind customers in the long term.

Strengthening the international business

Internationally NanoRepro AG distributes its products mainly through distributors and OEM agreements. Over the last two years, various strategic sales agreements have been concluded for important regions, the tests are already in the approval process, and the first countries have already been delivered after successful approval. Through an optimized selection of distributors and new contract negotiations, the company sees significant growth potential in establishing the NanoRepro brand internationally.

Long list of well-known international B2B customers

Over the last few years, NanoRepro AG has been able to win strong partners such as Paul Hartmann AG or Glenmark Pharmaceuticals as customers who pursue an internationally strong sales strategy and continuously expand their portfolio through newly approved products and additional countries.

Introduction of trade marks established German sales network

Within the last few years, NanoRepro AG has set up a wide distribution network in Germany, which, in addition to pharmacy wholesale, an online shop and free trade representatives, also covers direct sales to pharmacies and doctors as well as hospitals and offers OEM manufacturing for larger sales partners. In addition, the Company prepares its entry into trading. First pilot projects for food and drugstore chains are already under way.

Restructuring the company bears fruit

The turnover developed from € 450,000 in 2015 to € 1,550,000 in 2016 and it shows that the restructuring of recent years is bearing fruit. Now we are in an excellent position to establish ourselves as a high-quality provider of innovative diagnostics internationally, both in the areas of development as well as production and distribution. From now on, scale effects can be achieved.

Sprache / Language Mobile

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.